



Shilpa Medicare Limited

Corporate & Admin Office:

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

Date: 5 July, 2024

To,

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai-400 051

Stock Code: NSE: SHILPAMED/BSE-530549

Dear Sir/Madam,

Sub: Analysts / Investors' call.

Ref: Regulation 30 of the Securities and Exchange Board of India (LODR) Regulations, 2015

This is to inform that the Company representatives would have a call with Analysts / Investors, the call details of which are as enclosed.

Please note that this call is only to provide certain additional information on the intimation by the Company on 4 July, 2024 regarding an Important milestone for the CDMO business of Shilpa Medicare Limited (SML) and is therefore an extension of the said intimation. Consequently, no presentation is proposed to be made on this call.

The Management of the Company has decided to take this route to dispense the background to the investors and public at large in the interest of corporate governance and improving transparency.

In compliance with the provisions of the Listing Regulations, the audio recordings and the transcript would be made available on the website of the Company and also communicated to the stock exchanges.

This is for your information as also for the information of your members and the public at large.

Thanking you,

For SHILPA MEDICARE LIMITED

Ritu Tiwary
Company Secretary & Compliance Officer



Innovating for
affordable healthcare

Shilpa Medicare Limited Business Update Conference Call

Shilpa Medicare Limited will conduct a call to discuss a business update with respect to a CDMO arrangement for Oxylanthanum Carbonate (OLC), an NCE molecule.

The details of the conference call are:

Date:
July 8, 2024

Time:
11:00 AM IST

For **Diamond Pass Registration**: [LINK](#)

Local dial-in number	+91 22 6280 1130
	+91 22 7115 8031
International Toll Free Numbers	Hong Kong - 800 964 448
	Singapore - 800 101 2045
	UK - 0 808 101 1573
	USA - 1 866 746 2133

Details of the CDMO Business Update: [LINK](#)

For more information, **visit**: www.vbshilpa.com

For any queries please contact:

Shilpa Medicare:

Mr Dilip Kankani

Contact: +91 8532 238704

Email: dilipkankani@vbshilpa.com

EY IR :

Nachiket Kale/Runjhun Jain

Contact: +91 9920 940808/ 98207 20993

Email: nachiket.kale@in.ey.com /

runjhun.jain1@in.ey.com

About Shilpa Medicare Limited:

Shilpa Medicare Limited (SML) is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

Disclaimer:

Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward- looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, import duties, litigation, labour relations etc. Actual results might differ substantially from those expressed or implied. Shilpa Medicare Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.